Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2023 |
| Reihe/Periodikum: | JTO Clinical and Research Reports ; volume 4, issue 9, page 100543 ; ISSN 2666-3643 |
| Verlag/Hrsg.: |
Elsevier BV
|
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-29166600 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://dx.doi.org/10.1016/j.jtocrr.2023.100543 |
